In vivo evaluation of intravesical paclitaxel and combined bcl-xL antisense oligodeoxynucleotide treatment for orthotopic urothelial carcinoma.
Standard
In vivo evaluation of intravesical paclitaxel and combined bcl-xL antisense oligodeoxynucleotide treatment for orthotopic urothelial carcinoma. / Bolenz, Christian; Weiss, Christel; Wenzel, Melanie; Gabriel, Ute; Steidler, Annette; Becker, Andreas; Herrmann, Edwin; Trojan, Lutz; Michel, Maurice Stephan.
In: J CANCER RES CLIN, Vol. 135, No. 5, 5, 2009, p. 679-686.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - In vivo evaluation of intravesical paclitaxel and combined bcl-xL antisense oligodeoxynucleotide treatment for orthotopic urothelial carcinoma.
AU - Bolenz, Christian
AU - Weiss, Christel
AU - Wenzel, Melanie
AU - Gabriel, Ute
AU - Steidler, Annette
AU - Becker, Andreas
AU - Herrmann, Edwin
AU - Trojan, Lutz
AU - Michel, Maurice Stephan
PY - 2009
Y1 - 2009
N2 - PURPOSE: To evaluate intravesical paclitaxel monotherapy and combined treatment with antiapoptotic bcl-xL antisense oligodeoxynucleotides (AS-ODNs) on urothelial carcinoma (UC). METHODS: Forty-eight FoxN(rnu) athymic nude rats with orthotopic human bladder UC were randomized to four treatment groups [1, paclitaxel; 2, paclitaxel/bcl-xL AS-ODNs; 3, bcl-xL AS-ODNs (control); 4, medium (control)]. Three consecutive instillations were applied and weekly endoscopic tumor size measurements were performed. RESULTS: Significant tumor size reduction was achieved in groups 1 and 2 (each P <0.0001), whereas continuous UC growth was observed in control animals (groups 3 and 4; P <0.0001 and P <0.0020). Complete tumor eradication was achieved in four treated animals (groups 1 and 2). No significant difference in chemoresection effects was found between groups 1 and 2 (P = 0.2251). CONCLUSIONS: We present an in vivo evaluation of intravesical treatment with paclitaxel and combined bcl-xL AS-ODNs. Despite efficient tumor size reduction, no gain was observed when adding bcl-xL AS-ODNs in this experimental setting.
AB - PURPOSE: To evaluate intravesical paclitaxel monotherapy and combined treatment with antiapoptotic bcl-xL antisense oligodeoxynucleotides (AS-ODNs) on urothelial carcinoma (UC). METHODS: Forty-eight FoxN(rnu) athymic nude rats with orthotopic human bladder UC were randomized to four treatment groups [1, paclitaxel; 2, paclitaxel/bcl-xL AS-ODNs; 3, bcl-xL AS-ODNs (control); 4, medium (control)]. Three consecutive instillations were applied and weekly endoscopic tumor size measurements were performed. RESULTS: Significant tumor size reduction was achieved in groups 1 and 2 (each P <0.0001), whereas continuous UC growth was observed in control animals (groups 3 and 4; P <0.0001 and P <0.0020). Complete tumor eradication was achieved in four treated animals (groups 1 and 2). No significant difference in chemoresection effects was found between groups 1 and 2 (P = 0.2251). CONCLUSIONS: We present an in vivo evaluation of intravesical treatment with paclitaxel and combined bcl-xL AS-ODNs. Despite efficient tumor size reduction, no gain was observed when adding bcl-xL AS-ODNs in this experimental setting.
M3 - SCORING: Zeitschriftenaufsatz
VL - 135
SP - 679
EP - 686
JO - J CANCER RES CLIN
JF - J CANCER RES CLIN
SN - 0171-5216
IS - 5
M1 - 5
ER -
